🔗 Share this article

Ministers and senior MPs have expressed alarm that the United Kingdom's series of deals with Donald Trump are "lacking a solid foundation." This follows revelations that a recently announced deal on drug pricing, which commits to zero tariffs in exchange for the NHS paying more, lacks any detailed agreement beyond limited headline terms published in government press releases.

A Deal Without Detail

The deal on drug tariffs, promoted as a "generational" achievement, is still an "statement of intent" without a signed legal text. It has been highlighted that the official announcements from the UK and US governments frame the deal in divergent terms. The British version celebrates securing "duty-free access" as a singular success, while the American announcement dwells on the expectation for the NHS to pay significantly more for new medications.

"There is a serious risk that the UK government has agreed to terms to increase medicine costs in return for nothing more than a assurance from President Trump," said David Henig, a trade policy analyst. "We know he has form for not following through on agreements."

Broader Instability and a Paused Tech Deal

Concerns have been amplified by Washington's move to pause the major technology agreement, which was previously heralded as "a generational step-change" in the bilateral relationship. The US pointed to a failure to advance from the UK on lowering trade barriers as the reason for the pause.

In a separate development, concessions agreed to for British farmers as part of an earlier tariff deal have yet to be formally approved by the US, despite a looming January deadline. "Our understanding is that the US has failed to approve the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Privately, ministers have voiced worries that the government's deals with Washington are lacking substance. One minister reportedly said the series of agreements as "resting on shaky ground," while another characterized the situation as the "prevailing condition" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, argued: "The only thing more surprising than Trump's temper tantrums is the UK government's optimistic assumption that his administration is a trustworthy negotiator. The NHS is of vital importance."

Official Reassurances and Concrete Outcomes

Ministry sources have sought to reduce the possibility of the US backing out of the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been pushing for the agreement, wanting clarity on imports and pricing, making it more concrete than the paused tech deal.

Officials concede that instability is a feature of dealing with the current US leadership. However, they contend that the UK has obtained tangible results for businesses, such as preferential tariff rates compared to other nations. "Securing 25% steel tariffs, which is lower than the rate for the rest of the world, is a concrete advantage," one official said.

Yet, problems have surfaced in enacting the initial US-UK accord. Promised quotas on beef exports have yet to be finalized, and the commitment to "reduce steel tariffs to zero" has is still pending, with tariffs remaining at 25%.

Looking ahead, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.